ASCO 2012 Breast Cancer Symposium home

Article

Cancer Network presents exclusive coverage from the annual American Society of Clinical Oncology (ASCO) Breast Cancer Symposium. Check out the stories below for write-ups of the most important information to come out of this year's event.

Cancer Network presents exclusive coverage from the annual American Society of Clinical Oncology (ASCO) Breast Cancer Symposium. Check out the stories below for write-ups of the most important information to come out of this year's event.

Related Videos
Saad Usmani, MD, MBA, FACP, an expert on multiple myeloma
Donna Catamero, ANP-BC, OCN, CCRC, an expert on multiple myeloma
Marwan G. Fakih, MD, and Atif Hussein, MD, MMM, FACP, experts on colorectal cancer
Marwan G. Fakih, MD, and Atif Hussein, MD, MMM, FACP, experts on colorectal cancer
Experts on MM
Joshua K. Sabari, MD, and Alexander I. Spira, MD, PhD, experts on non-small cell lung cancer
Related Content
The FDA has set a Prescription Drug User Fee Act date of April 5, 2024 for nivolumab plus chemotherapy in unresectable or metastatic urothelial carcinoma.

Frontline Nivolumab/Chemo Earns FDA Priority Review in Urothelial Carcinoma

December 5th 2023
Article

The FDA has set a Prescription Drug User Fee Act date of April 5, 2024 for nivolumab plus chemotherapy in unresectable or metastatic urothelial carcinoma.

Govindarajan Narayanan, MD, speaks to the potential time-saving advantages of using the Epione robot for microwave ablation, cryoablation, and other surgical strategies in patients with liver cancer and other tumors.

Adapting to a Robotic Workstation for Image-Guided Liver Cancer Surgery

December 4th 2023
Podcast

Govindarajan Narayanan, MD, speaks to the potential time-saving advantages of using the Epione robot for microwave ablation, cryoablation, and other surgical strategies in patients with liver cancer and other tumors.

Investigators will assess LP-284 as a treatment for those with B-cell non-Hodgkin lymphoma in a phase 1 trial.

FDA Grants Orphan Drug Designation to LP-284 in High-Grade B-Cell Lymphoma

December 5th 2023
Article

Investigators will assess LP-284 as a treatment for those with B-cell non-Hodgkin lymphoma in a phase 1 trial.

Personalized therapy tailored for mutation status is something to expect in the coming years for colorectal cancer treatment, notes Tanios S. Bekaii-Saab, MD.

Tanios S. Bekaii-Saab, MD, Speaks to Expanding Horizons in CRC Treatment

November 27th 2023
Podcast

Personalized therapy tailored for mutation status is something to expect in the coming years for colorectal cancer treatment, notes Tanios S. Bekaii-Saab, MD.

The safety profile of venetoclax following allogeneic hematopoietic stem cell transplantation in patients with chronic lymphocytic leukemia appears to be comparable with other reports in clinical trials.

Venetoclax Yields Responses After alloHSCT in Small Relapsed CLL Cohort

December 4th 2023
Article

The safety profile of venetoclax following allogeneic hematopoietic stem cell transplantation in patients with chronic lymphocytic leukemia appears to be comparable with other reports in clinical trials.

If approved, UGN-102 may become the first non-surgical option for patients with low-grade intermediate-risk non–muscle invasive bladder cancer, says Sandip Prasad, MD.

UGN-102 Yields Complete Responses in Non-Muscle Invasive Bladder Cancer

December 4th 2023
Article

If approved, UGN-102 may become the first non-surgical option for patients with low-grade intermediate-risk non–muscle invasive bladder cancer, says Sandip Prasad, MD.